Published: May 2017
-Non-Invasive Cancer Diagnostics
Roots Analysis has announced the addition of “Non-Invasive Cancer Diagnostics Market (2nd Edition), 2017-2030” report to its list of offerings. The report provides a comprehensive analysis of the current landscape and future outlook of the growing market of liquid biopsy and other non-invasive tests being developed for the treatment of cancer.
Deepanshu Jain, the principal analyst, stated, “Liquid biopsy has emerged as a promising non-invasive cancer diagnostic tool that analyzes biofluids to detect rare cells and biomarkers, such as circulating tumor cells (CTCs), circulating tumor DNA / RNA (ctNAs) or exosomes. In addition to liquid biopsy, the market is gradually witnessing the emergence of several other non-invasive diagnostic technologies that exploit skin lesions, bronchial fluid and exhaled breath as samples to trace signatures of cancer.”
The market is primarily led by start-ups / small companies, such as (in alphabetical order) CellMax Life, Celsee Diagnostics, Datar Genetics, DiaDx, EONE-DIAGNOSTICS Genome Center, Exosome Sciences, iCellate Medical, Inivata, IVDiagnostics, LCM Genect and MDNA Life Sciences. It also has presence of mid to large-sized pharma players; notable examples include (in alphabetical order) Biocartis, Counsyl, Foundation Medicine, Genomic Health and NeoGenomics Laboratories. In addition to the aforementioned players, a number of pharma giants are also developing assets in this field. Prominent players under this category include (in alphabetical order) Affymetrix, Menarini Silicon Biosystems, Myriad Genetics, QIAGEN, Roche, Siemens Healthineers and Thermo Fisher Scientific. The report, amongst other things, covers the following:
Jain further added, “The likely benefits associated with the use of non-invasive cancer diagnostics for early diagnosis / patient monitoring / recurrence monitoring are estimated to be worth billions of dollars. These non-invasive diagnostic tests, backed by patient success stories, increasing awareness and the availability of successful clinical validation data for several cancer indications, offer significant promise and are anticipated to replace invasive diagnostic tools/techniques in the coming few years. With liquid biopsy on the forefront, the overall non-invasive cancer diagnostics market is likely to receive a significant boost in the foreseen future.”
The report highlights the contributions of several players in the field, including the following:
The opinions and insights discussed in this report were influenced by valuable inputs from senior stakeholders in the industry. The report features detailed transcripts of interviews held with Burkhard Jansen, MD (Chief Medical Officer, DermTech), Frank Szczepanski (President and CEO, IVDiagnostics), Riccardo Razzini (Sales and Marketing Manager, LCM Genect), Nathalie Bernard (Marketing Director, OncoDNA), Abizar Lakdawalla (Founder, ProXeom), Mark Li (CEO, Resolution Bioscience), Christer Ericsson (Chief Scientific Officer, iCellate Medical), Philippe Nore (CEO and Co-founder, MiNDERA) and Jake Micallef (Chief Scientific Officer, VolitionRx).
For additional details, please visit
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry